Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGallego Plazas, Javier
dc.contributor.authorArias-Martinez, A.
dc.contributor.authorLecumberri, A.
dc.contributor.authorMartínez de Castro, Eva
dc.contributor.authorCustodio, Ana
dc.contributor.authorCano, Juana Maria
dc.contributor.authorDiez Garcia, Marc
dc.date.accessioned2022-09-12T08:05:43Z
dc.date.available2022-09-12T08:05:43Z
dc.date.issued2022-06
dc.identifier.citationPlazas JG, Arias-Martinez A, Lecumberri A, Martínez de Castro E, Custodio A, Cano JM, et al. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. ESMO Open. 2022 Jun;7(3):100514.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/8135
dc.descriptionGastroesophageal cancer; Gender; Sex
dc.description.abstractBackground Recommendations for research articles include the use of the term sex when reporting biological factors and gender for identities or psychosocial or cultural factors. There is an increasing awareness of incorporating the effect of sex and gender on cancer outcomes. Thus, these types of analyses for advanced gastroesophageal adenocarcinoma are relevant. Patients and methods Patients with advanced gastroesophageal adenocarcinoma from the Spanish AGAMENON-SEOM registry treated with first-line combination chemotherapy were selected. Epidemiology, characteristics of the disease, treatment selection, and results were examined according to sex. Results This analysis included 3274 advanced gastroesophageal adenocarcinoma patients treated with combination chemotherapy between 2008 and 2021: 2313 (70.7%) men and 961 (29.3%) women. Tumors in females were more frequently HER2-negative (67.8% versus 60.8%; P < 0.0001), grade 3 (45.4% versus 36.8%; P < 0.001), diffuse (43.3% versus 26.5%; P < 0.0001), and signet ring cell histology (40.5 versus 23.9%; P < 0.0001). Peritoneal spread was more common in women (58.6% versus 38.9%; P < 0.0001), while liver burden was lower (58.9% versus 71.1%; P < 0.0001). There were no significant differences in treatment recommendation. Treatment doses, density, and duration were comparable between sexes. Women experienced more diarrhea (46% versus 37%; P < 0.0001), neutropenia (51% versus 43%; P < 0.0001), and anemia (62% versus 57%; P < 0.0001). After a median 59.6-month follow-up [95% confidence interval (CI) 54.5-70.8], there were no statistically significant differences between the sexes in progression-free survival [6.21 months (95% CI 5.8-6.5 months) versus 6.08 months (95% CI 5.8-6.3 months); log-rank test, χ2 = 0.1, 1 df, P = 0.8] or in overall survival [10.6 months (95% CI 9.8-11.1 months) versus 10.9 months (95% CI 10.4-11.4 months); log-rank test: χ2 = 0.6, 1 df, P = 0.5]. Conclusion This sex analysis of patients with advanced gastroesophageal adenocarcinoma from the AGAMENON-SEOM registry receiving first-line polychemotherapy found no differences in survival. Although women had worse prognostic histopathology, metastatic disease pattern, and greater toxicity, treatment allocation and compliance were equivalent.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;7(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEsòfag - Càncer - Tractament
dc.subjectEstómac - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshAdenocarcinoma
dc.subject.meshEsophageal Neoplasms
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleSex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2022.100514
dc.subject.decsadenocarcinoma
dc.subject.decsneoplasias del esófago
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2022.100514
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Plazas JG] Medical Oncology Department, Hospital General Universitario de Elche, Elche. [Arias-Martinez A] Pharmacy Department, Hospital Universitario Germans Trias i Pujol, Barcelona. [Lecumberri A] Medical Oncology Department, Hospital Universitario de Navarra, Pamplona. [Martínez de Castro E] Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander. [Custodio A] Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid. [Cano JM] Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real. [Diez M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35714478
dc.identifier.wos000836447800006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record